The EPS projection of CEPHEID (NASDAQ:CPHD) for period quarter completed 2016-12-31 is $0.01.
The EPS estimates given a week and 30-days ago were $0.01 and $0.01 correspondingly. This number 60 and 90 days before was $0.01 and $0.01 respectively. However, over last week ago, the change in EPS estimate is 0%.
For the quarter completed 2 mean estimate is $0.01 based on 3 EPS estimations. As on 2016-07-28 estimated EPS stood at $-0.09 showing surprise of $0.05, or 35.71%. Following the disclosed forecasts, the standard deviation is $0.06.
The upgrade in EPS revisions were 0 a week earlier against negative revisions of 0. In last 1- month and 60-days, the upgrade in EPS revisions were 0 and 1 correspondingly, whereas for a quarter and 120-days earlier, it was 2 and 2 in that sequence.
The negative revisions of earnings per-share in the last 1-month and 60-days were 0 and 0 in that order. However, a quarter and 120-days earlier, this count was 0 and 0 correspondingly.
EPS revisions downgrade and upgrade in the last 18 days were 0 and 2, correspondingly.
Quarterly Sales Estimates
The arithmetic mean of apparent annual sales of CEPHEID (NASDAQ:CPHD) is $199.347 and the median is $200.812. The estimate is stated by 5 analysts for the fiscal 2017.
The highest yearly projection is $205.826 and lowest sales mark is $187. This results a standard deviation of $7.34.
Almost 5 have revised sales target positively in the past week and 5 have downgraded forecasts. Depending on the stated estimates, the calculated change in target against the past week is 0%.
Nearly 5 revised sales projections positively over the past month and 5 have downgraded forecasts. It leads to a mean estimate deviation of 0%.
Just about 5 have revised sales forecast positively over the quarter and 5 have downgraded forecasts, giving a deviation of -1.363%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...